Extended Data Table 2 Viruses and antigens used in the microneutralization (MN) assay, the hemagglutination inhibition (HI) assay, and the fluorescent bead-based multiplex immunoassay (FMIA)
Virus or antigen name | GISAID isolate ID | HA accession number | Subtype | HA clade | Full virus or RG or HA | Passage history | Origin of the virus or HA | Biosafety level handling | Method |
|---|---|---|---|---|---|---|---|---|---|
A/Astrakhan/3212/2020 CVV | EPI_ISL_13655139 | EPI2084527 | A(H5N8) | 2.3.4.4.b | IDCDC-RG71A | E1M2 | The Crick Worldwide Influenza Centre, London (Ex/E1) | BSL2+ | MN |
A/Astrakhan/3212/2020 | EPI_ISL_1038924 | EPI1846961 | A(H5N8) | 2.3.4.4.b | 7+1 PR/8 HY | 293TM2 | Gene synthesis from Proteogenix | BSL2 | HI |
A/blue fox/UH/004/2023 | EPI_ISL_18764855 (E1 passage) | EPI2914899 (E1 passage) | A(H5N1) | 2.3.4.4.b | Full virus | M2 | Associate Professor Tarja Sironen, University of Helsinki | BSL3 | MN |
A/Texas/37/2024 | EPI_ISL_19027114 | EPI3171488 | A(H5N1) | 2.3.4.4.b | 7+1 PR/8 HY | 293TM2 | Plasmid from Dr. Daniel R. Perez, University of Georgia, US | BSL2 | HI |
A/Michigan/90/2024 | EPI_ISL_19162802 | EPI3334182 | A(H5N1) | 2.3.4.4.b | HA amino acids 1-530 | Original | Antigen from Native Antigen Company | BSL1 | FMIA |
